A331920 Stock Overview
Designs, manufactures, and distributes sequencing kits. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Celemics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,450.00 |
| 52 Week High | ₩10,400.00 |
| 52 Week Low | ₩3,195.00 |
| Beta | 0.80 |
| 11 Month Change | -21.77% |
| 3 Month Change | -45.41% |
| 1 Year Change | 6.15% |
| 33 Year Change | -75.53% |
| 5 Year Change | n/a |
| Change since IPO | -86.63% |
Recent News & Updates
Celemics (KOSDAQ:331920) Is Posting Solid Earnings, But It Is Not All Good News
Aug 26
We're Not Very Worried About Celemics' (KOSDAQ:331920) Cash Burn Rate
Jul 29Here's Why We're Not Too Worried About Celemics' (KOSDAQ:331920) Cash Burn Situation
Mar 28Recent updates
Celemics (KOSDAQ:331920) Is Posting Solid Earnings, But It Is Not All Good News
Aug 26We're Not Very Worried About Celemics' (KOSDAQ:331920) Cash Burn Rate
Jul 29Here's Why We're Not Too Worried About Celemics' (KOSDAQ:331920) Cash Burn Situation
Mar 28What You Need To Know About Celemics, Inc.'s (KOSDAQ:331920) Investor Composition
Dec 17Shareholder Returns
| A331920 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 3.6% | -7.6% | -0.7% |
| 1Y | 6.2% | 32.0% | -4.1% |
Return vs Industry: A331920 underperformed the KR Life Sciences industry which returned 32% over the past year.
Return vs Market: A331920 exceeded the KR Market which returned -4.1% over the past year.
Price Volatility
| A331920 volatility | |
|---|---|
| A331920 Average Weekly Movement | 11.4% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A331920's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A331920's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 39 | Young-hoon Lee | www.celemics.com |
Celemics, Inc. designs, manufactures, and distributes sequencing kits. The company offers BRCA, somatic mutation cancer, and hereditary cancer kits; and NGS Library preparation kits. It also provides customized target enrichment kit, next generation sequencing, NGS unit, and NGS-lab building consulting services.
Celemics, Inc. Fundamentals Summary
| A331920 fundamental statistics | |
|---|---|
| Market cap | ₩28.57b |
| Earnings (TTM) | ₩11.01b |
| Revenue (TTM) | ₩6.08b |
2.6x
P/E Ratio4.6x
P/S RatioIs A331920 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A331920 income statement (TTM) | |
|---|---|
| Revenue | ₩6.08b |
| Cost of Revenue | ₩3.65b |
| Gross Profit | ₩2.43b |
| Other Expenses | -₩8.58b |
| Earnings | ₩11.01b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.35k |
| Gross Margin | 39.98% |
| Net Profit Margin | 181.03% |
| Debt/Equity Ratio | 0% |
How did A331920 perform over the long term?
See historical performance and comparison